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E-mail address: gowrana@tcd.ie (A. Gowran).The phytocannabinoid D9-Tetrahydrocannabinol (D9-THC), the main psychoactive cannabinoid in
cannabis, activates a number of signalling cascades including p53. This study examines the role of
D9-THC in regulating the p53 post-translational modiﬁer proteins, Murine double minute (Mdm2)
and Small Ubquitin-like MOdiﬁer protein 1 (SUMO-1) in cortical neurons. D9-THC increased both
Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid
receptor type 1 (CB1)-receptor dependent manner. We demonstrate that D9-THC decreased the
SUMOylation of the CB1 receptor. The data reveal a novel role for cannabinoid receptor activation
in modulating the SUMO regulatory system.
Structured summary:
MINT-7266621: Cb1 (uniprotkb:P20272) physically interacts (MI:0915) with SUMO-1 (uniprotkb:Q5I0H3)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7266633: SUMO-1 (uniprotkb:Q5I0H3) and Cb1 (uniprotkb:P20272) colocalize (MI:0403) by ﬂuo-
rescence microscopy (MI:0416)
MINT-7266611: p53 (uniprotkb:P10361) physically interacts (MI:0915) with SUMO-1 (uniprotkb:Q5I0H3)
by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
D9-Tetrahydrocannabinol (D9-THC) is the main psychoactive
component of Cannabis sativa [1–3]. D9-THC activates the cannab-
inoid receptor type 1 (CB1) which is expressed in the central ner-
vous system. CB1 is a G-protein coupled receptor that regulates
ion channels and activates multiple signal transduction mecha-
nisms [4]. The ability of cannabinoids to promote cell death and
cell survival is an intriguing aspect of cannabinoid action [5]. Can-
nabinoid-induced neurotoxicity has been reported in neurones [6–
9] and in the neonatal cerebral cortex [10]. Contrary to this, D9-
THC has neuroprotective effects [11].
The tumour suppressor protein, p53, has a central role in cell
cycle arrest or apoptosis in response to a variety of stressors
[12,13]. The activity of p53 can be titrated at many levels includingchemical Societies. Published by E
CB1, the cannabinoid recep-
-1, Small Ubquitin MOdiﬁer
, any amino acid; E, glutamic
Western immunoblot; IP,transcriptional control, alterations in protein half-life and post-
translational modiﬁcations [14]. Post-translational modiﬁcations
of p53 allow cells to rapidly activate a unique set of responses to
diverse stress stimuli [15]. In unstressed cells, p53 is present in a
latent state and is maintained at low levels through targeted deg-
radation by association with Murine double minute 2 (Mdm2) [16].
The pro-apoptotic function of p53 is induced by phosphorylation of
serine 15 which we have previously reported to occur in neurones
treated with D9-THC [7,8]. Phosphorylation of serine 15 also inhib-
its the interaction between p53 and Mdm2 [17].
The post-translational modiﬁcation of p53 with the Small Ubiq-
uitin-related MOdiﬁer protein 1 (SUMO-1) affects the activity of
p53 [18,19]. SUMO-1 binds covalently to lysine residues located
within a SUMOylation consensus motif located in multiple sub-
strate proteins [20]. SUMO-1 binds to the C-terminus of p53 within
the SUMO conjugation motif (WKXE) [21]. Contrary to reports of
the positive effects of SUMOylation on p53 transactivation
[18,19], it has been demonstrated that SUMOylation of p53 de-
creases the strength of the interaction between p53 and Mdm2
[22]. Although p53 was one of the ﬁrst proteins that SUMOylation
was demonstrated, the physiological relevance of this modiﬁcation
remains enigmatic [21]. Protein SUMOylation has a role in a num-lsevier B.V. All rights reserved.
A. Gowran et al. / FEBS Letters 583 (2009) 3412–3418 3413ber of physiological processes, including nuclear transport [23],
cell cycle control [24] and synaptic transmission [25]. Furthermore,
recent reports have implicated the SUMO regulatory processes in
neurodegeneration [26]. Given the role for cannabinoids in control-
ling neuronal fate and synaptic function [27,28] we examined
whether activation of the cannabinoid system by D9-THC affected
the expression of Mdm2 or SUMO-1 in primary neurones. Further-
more, we investigated if the SUMOylation status of p53 and CB1
were altered by D9-THC.
2. Methods
2.1. Culture of cortical neurones
Primary neurones were established as previously described
[7,8].
2.2. Drug treatments
D9-THC was obtained from Sigma–Aldrich Company Ltd. and
diluted to 5 lMwith culture media [7,8]. Neurones were incubated
with the selective CB1 antagonist AM251 (10 lM; [7,8,29], Tocris
Cookson Ltd.) for 30 min before D9-THC treatment.
2.3. Western immunoblot
Neurones were harvested in lysis buffer as previously described
[7,8] and supplemented with NP-40 (0.5%) and SDS (10%) for deter-
mination of SUMO-1 expression. Proteins were separated by elec-
trophoresis, transferred to nitrocellulose and detected with
speciﬁc antibodies for Mdm2 (1:500; Abcam) or SUMO-1 (1:500;
Abcam) followed by horse radish peroxidase (HRP)-conjugated
anti-rabbit IgG (1:500/1:800) and enhanced chemiluminescence.
Blots were exposed to X-ray ﬁlm followed by imaging and quanti-
ﬁcation using Lab works image acquisition and analysis software
(UVP Bioimaging systems). Blots were stripped and re-probed for
b actin. Data are expressed as ratios of target protein/b actin using
arbitrary units. Unknown molecular weights were read from a
standard curve plotted from the distances travelled by molecular
weight markers against their molecular weights (250–7 kDa).
2.4. Immunocytochemistry
Neurones were ﬁxed with 4% paraformaldehyde, permeabilised
with 0.2% Triton X-100 and blocked in PBS containing 20% horse or
10% goat serum for Mdm2/SUMO-1, respectively. Proteins were la-
belled with speciﬁc antibodies for Mdm2 (1:800; Chemicon) or
SUMO-1 (1:100; Santa Cruz Biotechnology Inc.) followed by biotin-
ylated goat anti-mouse IgG (1:500/1:200) and avidin-conjugated
ALEXA488 (1:50). Incorporated ﬂuorophores were examined by
confocal microscopy using appropriate excitation wavelengths
and ﬁlters.
2.5. Immunoprecipitation
Protein was prepared (600 lg/ml) as previously described [30]
was incubated with 5 lg of goat anti-total p53 antibody or goat
anti-CB1 (N19/N15, respectively; Santa Cruz Biotechnology Inc.).
Immune complexes were obtained by adding 50 ll TrueBlotTManti-
goat IgG beads (eBiosciences). Bound protein was eluted by heating
samples in sample buffer, separated by electrophoresis, transferred
to nitrocellulose and blocked in 5% non-fat milk (NFM) in buffer A
(25 mM Tris–HCl, pH 7.3, 0.15 M NaCl, 0.1% Tween-20). Blots were
probed for SUMO-1 (1:400; Abcam), total p53 (1:500; R19; Santa
Cruz Biotechnology Inc.) or CB1 (1:1000; N15; Santa Cruz Biotech-nology Inc.) followed by detection with HRP-conjugated secondary
IgG (1:400; 1:1800; 1:1500). All dilutions were with 0.5% NFM in
buffer A. Immunoreactive bands were detected and quantiﬁed as
in Section 2.3.
2.6. Colocalisation of CB1/SUMO-1
Following SUMO-1 labelling (Section 2.4) CB1 was labelled with
goat anti-CB1 (1:500 in 10% horse serum; N15; Santa Cruz Biotech-
nology Inc.) followed by biotinylated anti-goat IgG (1:500 in 10%
horse serum) and ExtrAvidin-R-Phycoerythrin (1:50). Coverslips
analysed as in Section 2.4.
2.7. In silico protein SUMOylation site prediction
CB1 protein sequence (GenBank: AAA99067.1) was searched for
potential SUMOylation sites using two algorithms: SUMOplotTM
(http://www.abgent.com/tools/sumoplot) and SUMOsp v2.0
(http://sumosp.biocuckoo.org/) [31] using a medium threshold le-
vel for SUMOsp v2.0.
2.8. Statistics
Data are reported as the means ± S.E.M. of the number of exper-
iments indicated in each case. For comparisons between relevant
treatments an un-paired Student’s t-test was performed using
Graph Pad Prism 5.
3. Results
3.1. D9-THC evokes an increase in Mdm2
The effect of D9-THC treatment (5 lM; 5–120 min) on Mdm2
expression was assessed (Fig. 1). The Mdm2 antibody was immu-
noreactive against (i) a 72 kDa isoform of Mdm2 generated from
one of the p53 response elements, (ii) a 60 kDa isoform corre-
sponding to the cleavage product generated from the full length
(90 kDa) Mdm2 and (iii) a 30 kDa C-terminal fragment of the
Mdm2 (Fig. 1B). D9-THC treatment only affected the expression
of p72Mdm2. Following D9-THC treatment for 5 min, p72Mdm2
expression was 2.33 ± 0.28 arbitrary units (mean ± SEM) which
was signiﬁcantly higher than in neurones treated with vehicle
(0.97 ± 0.33; P < 0.05, Student’s t-test, n = 6). This was not main-
tained at subsequent time points (15–120 min; Fig. 1A). Immuno-
cytochemistry demonstrated that Mdm2 was expressed after
5 min treatment with D9-THC and was localised within the cytosol
(Fig. 1C). We also observed that this response was CB1 dependent
(Fig. 1B, ii and Fig. 1C, v and vi).
3.2. D9-THC evokes an increase in unconjugated SUMO-1
To further establish the effect of D9-THC on the post-transla-
tional modiﬁers of p53, SUMO-1 expression was also assessed fol-
lowing treatment with D9-THC (5 lM; 5–120 min; Fig. 2A and B).
D9-THC evoked a time-dependent increase in the expression of
unconjugated SUMO-1. In neurones exposed to D9-THC for 5 min,
unconjugated SUMO-1 expression was 104.90 ± 17.07 arbitrary
units (mean ± SEM), comparable to neurones treated with vehicle
(81.27 ± 12.39). Following treatment with D9-THC for 15 min
unconjugated SUMO-1 expression was signiﬁcantly increased to
134.70 ± 17.49 (P < 0.05 vs. vehicle, Student’s t-test, n = 4). This ef-
fect was maintained after 30 min treatment with D9-THC
(126.20 ± 11.17; P < 0.05 vs. vehicle, Student’s t-test, n = 4). This
was not maintained at subsequent time points (60 and 120 min;
Fig. 2A). Fig. 2A also demonstrates that D9-THC increases unconju-
Fig. 1. D9-THC increases p72Mdm2. (A) a signiﬁcant increase in p72Mdm2 was found following treatment with D9-THC for 5 min and not at other time points (15–120 min).
Results are expressed as means ± S.E.M., *P < 0.05 vs. vehicle, Student’s t-test, n = 6. (B) (i) Representative blot demonstrating the induction of p72Mdm2 (arrow  72 kDa)
expression at 5 min (lane 2). Lane 1 represents vehicle-treated neurones, neurones treated with D9-THC for 15 min (lane 3), 30 min (lane 4), 60 min (lane 5) and neurones
treated with D9-THC for 120 min (lane 6). The p60Mdm2 cleavage product and C terminal fragment (p30) were also visible on the blot. b Actin expression was monitored to
ensure equal protein loading (bottom inset). (ii) Representative blot demonstrates that AM251 prevented the D9-THC-induced expression of p72Mdm2. p72Mdm2 is not
expressed in neurones treated with AM251 or D9-THC and AM251 (lanes 1 and 2; compared to lane 2 in B i). (C) Representative overlay images of Mdm2 immunoreactivity
(green) in neurones treated with (i) vehicle, and neurones exposed toD9-THC for (ii) 5 (iii) 15 and (iv) 30 min. Also neurones treated with AM251 (v), and neurones exposed to
AM251 and D9-THC (5 min, vi). Nuclei were stained with hoechst.
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THC-mediated increase in unconjugated SUMO-1 expression. Con-
jugated SUMO-1 indicated by the presence of a high molecular
weight smear was also increased (Fig. 2B, ii) reﬂective of D9-
THC-induced alterations in the overall SUMOylation status of pro-
teins. Immunocytochemistry revealed that SUMO-1 expression
was localised in the cytosol and nucleus in D9-THC-treated neuro-
nes (Fig. 2C, iii).
3.3. D9-THC induces the deSUMOylation of p53
Since SUMO-1 is a post-translational modiﬁer of p53, linked to
p53 transactivation, we assessed if D9-THC regulated the SUMOy-
lation status of p53. Immunoprecipitation was carried out to deter-
mine if D9-THC-induced the deSUMOylation of p53 (Fig. 3).Neurones were treated with D9-THC for 15 min in the presence
or absence of CB1 antagonist, AM251. D9-THC treatment for
15 min induced a signiﬁcant decrease in SUMOylated p53 levels
from 2551 ± 312 arbitrary units (mean ± SEM) in vehicle-treated
neurones to 1292 ± 145 following a 15 min exposure to D9-THC
(P < 0.01 vs. vehicle, Student’s t-test, n = 6). AM251 treatment alone
had no effect on SUMOylated p53 levels (2902 ± 295), however it
prevented the D9-THC-induced decrease in SUMOylated p53 levels
(2307 ± 306; P < 0.05 vs. D9-THC, Student’s t-test, n = 6). D9-THC
induced an increase in total p53 at 5 min (Fig. 3C, lane 2) compared
to control neurones (lane 1). The presence of bands greater than
53 kDa in control neurones are indicative of p53 conjugated to
interacting proteins, one of which is SUMO-1 (Fig. 3B). These bands
were not present in neurones treated with D9-THC for 5, 15 or
30 min (lanes 2, 3, and 4).
Fig. 2. D9-THC increases SUMO-1. (A) D9-THC signiﬁcantly increased unconjugated and conjugated SUMO-1 expression at 15 and 30 min but not at other time points (5, 60
and 120 min). Results are expressed as means ± S.E.M., *P < 0.05 vs. vehicle, Student’s t-test, n = 4. The D9-THC-induced increase in unconjugated SUMO-1 expression was
abrogated by CB1 antagonist AM251 (+P < 0.05 vs. D9-THC 15 min, Student’s t-test, n = 4). (B) (i) Representative blot showing the increase in unconjugated and conjugated
SUMO-1 expression in neurones exposed to D9-THC for 15 (lane 3) and 30 min (lane 4) compared to vehicle (lane 1) and neurones exposed to D9-THC for 5, 60 and 120 min
(lanes 2, 5 and 6). b Actin expression was monitored to ensure equal protein loading (bottom panel). (ii) D9-THC signiﬁcantly increases conjugated SUMO-1 after 15 and
30 min. Results are expressed as means ± S.E.M., *P < 0.05 vs. vehicle, Student’s t-test, n = 4. (C) Representative confocal images of SUMO-1 expression in neurones treated
with (i) vehicle, (ii) D9-THC for 5, (iii) 15 and (iv) 30 min. Differential interference contrast (DIC) images showing the total number of neurones present are also shown.
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Since D9-THC induces the deSUMOylation of p53 through CB1
and the publication of several reports showing agonist-induced
alterations in the SUMOylation status of many neuronal signallingreceptors, we investigated if CB1 contained potential SUMOylation
motifs and if the SUMOylation status of CB1 was altered byD9-THC.
In silico analysis of CB1 amino acid sequence revealed two poten-
tial SUMOlyation motifs (Fig. 4A). SUMOplotTM revealed two highly
probable motifs at lysine 43 (K43) and lysine 193 (K193; Fig. 4A, i).
Fig. 3. The effect of D9-THC on p53/SUMO-1 colocalisation. (A) Treatment with D9-
THC for 15 min induced a signiﬁcant decrease in SUMOylated p53. Pre-incubation
with AM251 prior to D9-THC exposure abolished the D9-THC-induced decrease in
SUMOylated p53 expression. Results are expressed as means ± S.E.M., **P < 0.01 vs.
vehicle, +P < 0.05 vs. D9-THC 15 min, Student’s t-test, n = 6). (B) Representative blot
demonstrating the decrease in SUMOylated p53 expression after 15 min of D9-THC
treatment (lane 2) compared to control neurones (lane 1). While AM251 had no
effect on SUMOylated p53 expression (lane 3), it abolished the ability of D9-THC to
decrease SUMOylated p53 expression (lane 4). (C) Representative blot demonstrat-
ing total p53 expression in the lysates. Total p53 was increased following 5 min of
D9-THC treatment (lane 2) compared to control neurones (lane 1). Bands greater
than 53 kDa were present in control neurones but not in neurones treated with D9-
THC for 5, 15 or 30 min (lanes 2, 3, and 4).
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roborating results achieved with SUMOplotTM. In control neurones,
immunocytochemistry demonstrated that SUMO-1 and CB1 were
colocalised within the perinuclear area and along neuronal pro-
cesses (Fig. 4B). In neurones treated with D9-THC (Fig. 4C)
SUMO-1 expression was increased whilst a marked internalisation
of CB1 was observed. Colocalisation between CB1 and SUMO-1 was
only observed in vehicle-treated neurones (Fig. 4B, iv) indicating
that CB1 is SUMOylated in the basal state and becomes deSUMOy-
lated upon activation by D9-THC. Immunoprecipitation of CB1 was
performed to validate this result (Fig. 4D, i). In control neurones
immunoreactive bands for SUMO-1 and CB1 were observed
(Fig. 4D, ii and iii, lane 1). In neurones treated withD9-THC we onlyobserved bands for CB1 (Fig. 4D, iii, lane 2) and not SUMO-1
(Fig. 4D, ii, lane 2) indicating that D9-THC induces the deSUMOyla-
tion of CB1.4. Discussion
We examined the effect ofD9-THC on the p53 post-translational
modiﬁers Mdm2 and SUMO-1. D9-THC induced an increase in the
expression of the p53-responsive protein, Mdm2, after 5 min coin-
ciding with the increase in phospho-p53ser15 which we have previ-
ously reported [7]. p53 acts as a transcription factor for Mdm2,
thus when activated, p53 transcriptionally upregulates Mdm2
expression [32]. Due to the ability of Mdm2 to inhibit p53, a neg-
ative feedback loop is formed providing a tight regulatory mecha-
nism [32]. We observed three isoforms of Mdm2, p72, p60 and p30.
This is unsurprising since the Mdm2 gene has two separate p53 re-
sponse elements each generating different Mdm2 isoforms (p90
and p72). Additionally, proteases can generate shorter Mdm2 iso-
forms (p60 and p30) [33,34]. The full length Mdm2 isoform
(p90Mdm2) is capable of binding and labelling p53 for degradation
whilst p72Mdm2 lacks a p53 binding site and so cannot act as a
p53 repressor [33]. This study demonstrates that D9-THC increases
the expression of the p72Mdm2, effectively activating p53 by pre-
venting its degradation [33]. This may account for the D9-THC-
mediated upregulation in p53 expression which we have previ-
ously reported to be essential for D9-THC-induced apoptosis
[7,8]. This effect of D9-THC could also reﬂect a transient stabilisa-
tion or neo-synthesis of this isoform. The p60Mdm2 and
p30Mdm2 isoforms that we observed are probably produced by
the action of a caspase-like enzyme, which is normally expressed
at high levels in cultured cells [35]. Our ﬁndings regarding the
induction of the Mdm2 protein provides corroborating evidence
that D9-THC modulates proteins that impact on p53 signalling. In
addition the observation that the p72Mdm2, which is incapable
of degrading p53, was upregulated provides a mechanism that
may allow for the ability of D9-THC to stabilise p53 during neuro-
nal apoptosis [7,8].
D9-THC signiﬁcantly increased the level of unconjugated and
conjugated SUMO-1 protein in a time-dependent manner with a
maximal response observed after 15–30 min of D9-THC treatment.
D9-THC induced the deSUMOylation of p53 which could be respon-
sible in part, for the aforementioned increase in overall unconju-
gated SUMO-1. AM251, ablated the effect of D9-THC on the
SUMOylation status of p53, indicating that deSUMOylation of
p53 involved CB1. The association of p53 with SUMO-1 is linked
to the regulation of the transcriptional activity [18,19], intracellu-
lar location [22] and the apoptotic potential of p53 [36]. However,
there have been conﬂicting reports as to the functional signiﬁcance
of this p53 modiﬁcation [21,37]. Its relevance has been questioned
since most SUMO targets, including p53, are modiﬁed at low levels
leaving a limited pool of unconjugated SUMO-1 [20,38]. However,
the role of modulating the SUMOylation status of p53 is perhaps a
more subtle modiﬁcation possibly acting in conjunction to other
post-translational modiﬁcations, e.g., interaction with other p53
interacting proteins. Our observations regarding increased levels
of conjugated SUMO-1 following D9-THC treatment may be reﬂec-
tive of this. Protein phosphorylation can act as a positive or nega-
tive signal for SUMOylation, e.g., the phosphorylation of c-Jun and
p53 induces their deSUMOylation [36,39]. These studies are of par-
ticular interest considering our previous ﬁndings regarding the D9-
THC-induced phosphorylation of p53 at serine 15 [7].
Cytoplasmic, nuclear and plasma membrane associated pro-
teins are modiﬁed by SUMO [40–42]. SUMOylation of the tran-
scription factor myocyte enhancer factor 2A plays a role in the
neuronal differentiation [43]. We have shown that D9-THC induces
Fig. 4. The effect of D9-THC on CB1/SUMO-1 colocalisation. (A) Potential SUMOylation motifs found after in silco experiments using SUMOplot
TM (i) and SUMOsp v2.0 (ii)
SUMOylation motif prediction alogrithms. (B) Representative images of ﬂuorescently labelled SUMO-1 (green; panel i) and CB1 (red; panel ii) in neurones treated with
vehicle. There was a marked colocalisation (yellow; panel iv) between SUMO-1 and CB1 on neuronal processes and around the cell body (arrows). Nuclei were stained with
hoechst (panel iii). (C) Representative images of ﬂuorescently labelled SUMO-1 (green; panel i) and CB1 (red; panel ii) in neurones treated with D9-THC for 15 min. Treatment
withD9-THC caused an overall increase in SUMO-1 and CB1 internalisation. There was a noticeable reduction in the amount of colocalisation between SUMO-1 and CB1 (panel
iv, yellow, arrows). Nuclei were stained with hoechst (panel iii). (D) (i) Treatment withD9-THC for 15 min decreased SUMOylated CB1. Results are expressed as means ± S.E.M.
of three observations. (ii) Representative blot demonstrating the presence of SUMO-1 in CB1 immunoprecipitates of control neurones (lane 1) and its absence in D9-THC
treated neurones (lane 2). (iii) Representative blot conﬁrming the presence of CB1 in the immunoprecipitates of control neurones (lane 1) and D9-THC treated neurones (lane
2).
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a pro-survival signal in neurones. Gibb et al. found that SUMOyla-
tion of the astroglial glutamate transporter EAAT2 causes the redi-
rection of the transporter to the nucleus which is responsible for
the transcriptional regulation of genes effecting astrocyte physiol-
ogy [44]. It has also been suggested that in neurones, SUMOylation
permits a rapid and reversible modiﬁcation of kainite receptor
membrane localisation and synaptic transmission [26]. Given that
CB1 is required for D9-THC-induced neuronal signalling and p53
SUMOylation, we also examined whether CB1 itself was a target
for SUMOylation. We identiﬁed potential SUMOylation motifs in
CB1 amino acid sequence. The motif involving K43 is highly likely
to be a SUMOylation motif due to the high accuracy of the SUMOsp
v2.0 algorithm [31]. It would be important to determine the impor-tance of this residue by performing experiments using cells
expressing K43 deﬁcient CB1. Immunocytochemistry and immuno-
precipitation (IP) demonstrated that SUMO-1 and CB1 were
colocalised, indicating that under basal conditions CB1 is SUMOy-
lated. D9-THC induced a marked decrease in the colocalisation be-
tween SUMO-1 and CB1 indicating that activation of CB1 induces its
deSUMOylation or the SUMOylation of a CB1 receptor-associated
protein.
Our ﬁndings raise the novel prospect that D9-THC can regulate
the SUMOylation of p53 and CB1 (see overview in Fig. 5). This is of
importance considering both phytocannabinoids and SUMO regu-
latory systems have been implicated in neurophysiological events
such as synaptic formation and function, regulation of receptor
numbers and neurodegeneration [26,44].
Fig. 5. Schematic representation of the effect D9-THC has on the post-translational
modifying proteins Mdm2 and SUMO-1. D9-THC induced an increase in the
p72Mdm2 which is incapable of labelling p53 for degradation. D9-THC also induced
an increase in unconjugated (S) and conjugated SUMO-1 (Sc) in a CB1 dependent
manner. CB1 becomes deSUMOylated upon treatment with D9-THC.
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